{"result": {"id": "c159e3a1-9d00-4e37-82ca-184aea521506", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"PCSK9 Inhibitors Community: 英克司兰, 托莱西单抗, 依洛尤单抗, and 阿利西尤单抗\",\n    \"summary\": \"This community is centered around PCSK9 inhibitors, a class of drugs used to lower cholesterol levels, with key entities including 英克司兰 (Inclisiran), 托莱西单抗 (Tolezumab), 依洛尤单抗 (Evolocumab), and 阿利西尤单抗 (Alirocumab). These entities are related through their shared mechanism of action as PCSK9 inhibitors and their applications in treating high cholesterol and related cardiovascular diseases. 英克司兰 stands out as the first small interfering RNA (siRNA) drug approved in China for cholesterol reduction, marking a significant advancement in lipid-lowering therapies.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the significant medical advancements and potential health benefits these drugs offer to patients with high cholesterol and cardiovascular diseases.\",\n    \"findings\": [\n        {\n            \"summary\": \"英克司兰 as a pioneering siRNA drug in China\",\n            \"explanation\": \"英克司兰 (Inclisiran) represents a breakthrough in cholesterol-lowering therapies as the first small interfering RNA (siRNA) drug approved in China for this purpose. Its approval in August 2023 marks a significant milestone in the treatment of high cholesterol, offering a novel mechanism of action that targets PCSK9 protein expression for durable LDL-C reduction. This drug provides a more convenient treatment option with less frequent dosing compared to traditional therapies. [Data: Entities (3014), Relationships (4810)]\"\n        },\n        {\n            \"summary\": \"Shared mechanism of action among community entities\",\n            \"explanation\": \"All key entities in this community, including 英克司兰, 托莱西单抗, 依洛尤单抗, and 阿利西尤单抗, function as PCSK9 inhibitors. This shared mechanism underlines their collective role in managing high cholesterol levels by reducing LDL-C concentrations, thereby addressing a critical risk factor for cardiovascular diseases. The relationships between these entities highlight the diversity within the PCSK9 inhibitor class, offering patients various treatment options based on individual needs and responses. [Data: Relationships (2543, 2538, 2541)]\"\n        },\n        {\n            \"summary\": \"Clinical benefits and patient convenience\",\n            \"explanation\": \"The PCSK9 inhibitors in this community offer significant clinical benefits, including substantial reductions in LDL-C levels and improved management of high cholesterol and cardiovascular disease risks. Notably, 英克司兰's less frequent dosing schedule enhances patient convenience and adherence, representing an important advancement in treatment options. These attributes underscore the community's impact on improving patient outcomes and quality of life. [Data: Entities (3014, 3013, 3011, 3012)]\"\n        },\n        {\n            \"summary\": \"Potential for broad patient applicability\",\n            \"explanation\": \"The drugs within this community are designed to serve a wide range of patients, particularly those who do not achieve desired LDL-C levels with statins or cannot tolerate statin therapy. This broad applicability enhances the community's impact, offering hope and improved treatment options for patients with challenging cholesterol management needs. The diversity in dosing regimens and mechanisms within the PCSK9 inhibitor class allows for personalized treatment approaches. [Data: Entities (3014, 3013, 3011, 3012)]\"\n        },\n        {\n            \"summary\": \"英克司兰's approval in China as a milestone\",\n            \"explanation\": \"The approval of 英克司兰 in China not only introduces a new treatment option but also signifies the country's openness to innovative therapies for cholesterol management. This milestone could pave the way for the introduction of more siRNA-based drugs in China, expanding the therapeutic landscape for various diseases. The event underscores the global nature of pharmaceutical innovation and its potential to benefit patients worldwide. [Data: Entities (3014), Relationships (4810)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752168729, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 868, "prompt_tokens": 2874, "total_tokens": 3742, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1472}, "prompt_cache_hit_tokens": 1472, "prompt_cache_miss_tokens": 1402}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n3014,英克司兰,\"英克司兰（Inclisiran）是一种小干扰RNA（siRNA）药物，属于PCSK9抑制剂，主要用于降低胆固醇水平。该药物于2023年8月在中国获批上市，适用于治疗成年人原发性高胆固醇血症和混合型血脂异常，尤其针对他汀类药物治疗后低密度脂蛋白胆固醇（LDL-C）未达目标值或不能耐受他汀类药物的患者。  \n\n英克司兰的作用机制是通过抑制PCSK9蛋白的表达，从而显著降低LDL-C水平，其降脂幅度与PCSK9单克隆抗体相近，但作用更为持久。相较于传统疗法，英克司兰的给药频率较低，为患者提供了更便利的治疗选择。  \n\n作为中国批准的首款用于降胆固醇的小干扰RNA药物，英克司兰代表了新一代降脂疗法的进展，为高胆固醇血症患者提供了新的治疗选择。\",5\r\n3013,托莱西单抗,\"托莱西单抗（Tolezumab）是一种PCSK9抑制剂，主要用于降低胆固醇水平。该药物通过抑制PCSK9蛋白活性，有效减少低密度脂蛋白胆固醇（LDL-C）的浓度，从而帮助管理高胆固醇血症及相关心血管疾病风险。托莱西单抗的推荐给药方案为每2周皮下注射一次，每次剂量为150 mg，临床研究表明其LDL-C降幅与其他同类药物相似。  \n\n作为PCSK9抑制剂类药物，托莱西单抗在降低LDL-C方面表现出显著疗效，适用于对他汀类药物不耐受或需要进一步降低胆固醇水平的患者。其作用机制和临床效果与其他已上市的PCSK9抑制剂（如阿利西尤单抗和依洛尤单抗）相近，但具体疗效和安全性可能因个体差异而有所不同。  \n\n综上，托莱西单抗是一种有效的降胆固醇药物，通过定期皮下注射给药，为高胆固醇患者提供了一种重要的治疗选择。\",4\r\n3011,依洛尤单抗,\"依洛尤单抗（Evolocumab）是一种PCSK9抑制剂，主要用于降低胆固醇水平。该药物通过抑制PCSK9蛋白的作用，有效减少低密度脂蛋白胆固醇（LDL-C）的浓度，从而帮助管理高胆固醇血症及相关心血管疾病风险。  \n\n依洛尤单抗的推荐剂量为140毫克，每两周一次，通过皮下注射给药。临床研究表明，该药物具有良好的安全性和耐受性，常见不良反应较轻，主要包括注射部位反应、鼻咽炎和上呼吸道感染等。  \n\n总体而言，依洛尤单抗是一种高效且耐受性良好的降胆固醇药物，适用于需要进一步降低LDL-C水平的患者，尤其是对他汀类药物反应不佳或不耐受的患者。\",4\r\n3012,阿利西尤单抗,\"阿利西尤单抗（Alirocumab）是一种PCSK9抑制剂，主要用于降低胆固醇水平。该药物通过抑制PCSK9蛋白的作用，有效减少低密度脂蛋白胆固醇（LDL-C）的浓度，从而帮助管理高胆固醇血症及相关心血管疾病风险。  \n\n阿利西尤单抗的推荐给药方案为每2周1次皮下注射，每次剂量为75 mg。临床研究表明，该药物具有良好的安全性和耐受性，常见不良反应较轻，主要包括注射部位反应（如疼痛或红肿）以及轻微的流感样症状。  \n\n总体而言，阿利西尤单抗是一种高效且耐受性良好的降胆固醇药物，适用于对他汀类药物反应不足或不耐受的患者，为心血管疾病的预防和治疗提供了重要选择。\",4\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n4810,英克司兰,中国,英克司兰于2023年8月在中国获批上市,20\r\n2543,托莱西单抗,英克司兰,Both are PCSK9 inhibitors,9\r\n2538,依洛尤单抗,阿利西尤单抗,Both are PCSK9 inhibitors,8\r\n2541,阿利西尤单抗,托莱西单抗,Both are PCSK9 inhibitors,8\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_e7fef76768f5653e33eabcb28dcd78f98d67ab7d3a28285f76d9fce62c148520_v2"}